Product Information

Within this section of the website, you will find patient information regarding our licensed products. These information sources include patient information leaflets, the summary of product characteristics and European Public Assessment Reports.

  • The patient information leaflets (PILs) provide important information for patients taking our licensed products.
  • The summary of product characteristics (SmPC) is a description of a medicinal product including recommendations for its use.
  • The European Public Assessment Report (EPAR) explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

Please note that this information is specific to the UK and is not intended to replace the advice of a qualified doctor or pharmacist.

Products
European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics
Abraxane® (paclitaxel formulated as albumin bound nanoparticles: nab-paclitaxel)European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics
Imnovid®▼ 1mg (pomalidomide)European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics
Imnovid®▼ 2mg (pomalidomide)Summary of Product Characteristics
Imnovid®▼ 3mg (pomalidomide)Summary of Product Characteristics
Imnovid®▼ 4mg (pomalidomide)Summary of Product Characteristics
Otezla®▼ 10mg, 20mg, 30mg (apremilast)European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics
Otezla®▼ 30mg (apremilast)Summary of Product Characteristics
Revlimid®▼ 2.5mg (lenalidomide)European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics
Revlimid®▼ 5mg (lenalidomide)Summary of Product Characteristics
Revlimid®▼ 7.5mg (lenalidomide)Summary of Product Characteristics
Revlimid®▼ 10mg (lenalidomide)Summary of Product Characteristics
Revlimid®▼ 15mg (lenalidomide)Summary of Product Characteristics
Revlimid®▼ 20mg (lenalidomide)Summary of Product Characteristics
Revlimid®▼ 25mg (lenalidomide)Summary of Product Characteristics
THALIDOMIDE CELGENE ™ (thalidomide)European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics
VIDAZA® (azacitidine)European Public Assessment ReportPatient Information LeafletSummary of Product Characteristics

ABRAXANE®, IMNOVID®, OTEZLA®, REVLIMID®, THALIDOMIDE CELGENE™ , VIDAZA® are registered trademarks of Celgene Corporation.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard (Freephone 0808 100 3352). By reporting side effects you can help provide more information on the safety of this medicine.


UK-CELG150025aa
Date of preparation: May 2015